Articles tagged "Immunosuppression"

2015 American Transplant Congress
10 Year Experience Using a Steroid Free Three Drug Maintenance Immunosuppression Regimen for Pancreas Transplant Alone: Comparison of Induction With Rabbit Antithymocyte Globulin +/- Rituximab
J. Fridell,¹ R. Mangus,¹ J. Chen,² M. Mujtaba,³ T. Taber,³ M. Goble,¹ J. Powelson.¹
¹Surgery, Indiana University School of Medicine, Indianapolis, IN; ²Pharmacy, Indiana University School of Medicine, Indianapolis, IN; ³Medicine, Indiana University School of Medicine, Indianapolis, IN.
Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two drug maintenance strategy may be…
2015 American Transplant Congress
Effect of Everolimus on Left Ventricular Hypertrophy in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
M. van der Giet,¹ H. Holdaas,¹ J. de Fijter,¹ A. Speziale,² C. Escrig,² G. Junge,² Z. Wang,³ J. Cruzado.¹
¹For the ELEVATE Study, Berlin, Germany; ²Novartis, Basel, Switzerland; ³Novartis Corporation, East Hannover, NJ.
Background: Left ventricular hypertrophy (LVH) is common in kidney transplant recipients (KTxR) and has shown to be a risk factor for death and heart failure…
2015 American Transplant Congress
Plasmapheresis – A Previously Unrecognised Risk Factor for BK Viraemia
E. Olayos,¹ K. Barraclough,² R. Walker,³ R. Masterson,² H. Peter,² C. Solomon.⁴
¹St Vincents Hospital, Fitroy, Victoria, Australia; ²Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia; ³Nephrology, The Alfred Hospital, Prahran, Victoria, Australia; ⁴Nephrology, Western Hospital, Footscray, Victoria, Australia.
BK nephropathy is an important preventable cause of graft loss, with the only universally accepted risk factor being overall burden of immunosuppression. In the absence…
2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
M. Gastaca, A. Valdivieso, J. Bustamante, P. Ruiz, J. Fernandez, A. Ventoso, M. Testillano, I. Palomares, P. Salvador, M. Prieto, A. Matarranz, M. Suarez, J. Ortiz de Urbina.
Liver Transplantation Unit, Cruces University Hospital. University of the Basque Country, Bilbao, Vizcaya, Spain.
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…
2015 American Transplant Congress
Relative In Vitro Immunoregulatory Effects of Everolimus, Sirolimus, Tacrolimus, Mycophenolic Acid and Drug Combinations
J. Mathew, X. Huang, J. Leventhal, L. Gallon, J. Miller, J. Levitsky.
Surgery - Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Everolimus (EVL) is a modified form of the mTOR-inhibitor Sirolimus (SRL) and is used clinically in combination with Mycophenolate (MMF) and/or Tacrolimus (TAC). The purpose…
2015 American Transplant Congress
Efficacy, Safety and Pharmacokinetics of Once-Daily, MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus (Prograf®) in De Novo Kidney Transplant Recipient Sub-Groups: A 2 Year Phase 3 Randomized, Double-Blind, Double-Dummy, Trial
S. Bunnapradist,¹ J. Denny,² M. Waybill,³ P. West-Thielke,⁴ S. Steinberg.⁵
¹David Geffen School of Medicine at UCLA, Los Angeles; ²Henry Ford Hospital, Detroit; ³Central Pennsylvania Transplant Foundation, Harrisburg; ⁴University of Illinois at Chicago, Chicago; ⁵California Institute of Renal Research, San Diego.
Differences in tacrolimus (tac) metabolism are evident in certain populations; in particular, lower tac bioavailability has been shown in females and black kidney transplant recipients…
2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ W. Lee,¹ G. Brandacher.¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria.
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…
2015 American Transplant Congress
Immunosuppression and Reoperation After Simultaneous Kidney Pancreas Transplantation Convey Greatest Risk for Rejection
C. Bratton, V. Rohan, S. Nadig, J. Mcgillicuddy, K. Chavin, P. Baliga, D. Taber.
MUSC, Charleston, SC.
Background: Episodes of acute cellular rejection (ACR) convey significant morbidity after simultaneous kidney and pancreas transplantation (SPK). The role of recipient sensitization, immunosuppression (IS) and…
2015 American Transplant Congress
Characterization of Peripheral Blood T and B Cells of Sensitized Kidney Transplant Recipients With Long Term Stable Graft Function
N. Galante,¹ M. Fernandes,¹ F. Agena,¹ A. Triboni,¹ G. Freitas,¹ A. Aguirre,¹ W. Nahas,¹ V. Coelho,² E. David-Neto.¹
¹Renal Transplant Service, Hospital das Clínicas - University of Sao Paulo School of Medicine, Sao Paulo, Brazil; ²Laboratory of Immunology, Heart Institute - University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
We examined the phenotype of T and B cells of peripheral blood of sensitized kidney transplant recipients with stable graft function (GFR > 29mL/min) enrolled…
2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ B. Bone,² H. Wijeweera,² D. Brennan.²
¹Barnes-Jewish Hospital, St. Louis; ²Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…